Inicio › Cáncer de vejiga › Oklahoma
Ensayos clínicos de Cáncer de vejiga en Oklahoma
12 estudios sobre Cáncer de vejiga buscan participantes en Oklahoma.
Ciudades en Oklahoma
Texto oficial del estudio (inglés)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT03866382Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07061964Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06770582Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT05334069The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
ReclutandoSe aceptan voluntarios sanos
Edades de 45 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT06995898FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Oklahoma - Health Sciences Center, Oklahoma City
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT05614739Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT07097142Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- University of Oklahoma Health Sciences Center, Oklahoma City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT07000084A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- OU Health Stephenson Cancer Center, Oklahoma City
- OU Medical Center, Oklahoma City
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT04879329A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 jul 2026 · NCT04389632Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT07327489SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.